These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 11305808)
1. Optimal hematocrit for the maximum oxygen delivery to the brain with recombinant human erythropoietin in hemodialysis patients. Hirakata H; Kanai H; Fukuda K; Tsuruya K; Ishida I; Kubo M; Hirano T; Hirakata E; Kuwabara Y; Fujishima M Clin Nephrol; 2000 May; 53(5):354-61. PubMed ID: 11305808 [TBL] [Abstract][Full Text] [Related]
2. Effect of normalization of hematocrit on brain circulation and metabolism in hemodialysis patients. Metry G; Wikström B; Valind S; Sandhagen B; Linde T; Beshara S; Långström B; Danielson BG J Am Soc Nephrol; 1999 Apr; 10(4):854-63. PubMed ID: 10203371 [TBL] [Abstract][Full Text] [Related]
3. CBF and oxygen metabolism in hemodialysis patients: effects of anemia correction with recombinant human EPO. Hirakata H; Yao H; Osato S; Ibayashi S; Onoyama K; Otsuka M; Ichiya Y; Kuwabara Y; Masuda Y; Fujishima M Am J Physiol; 1992 May; 262(5 Pt 2):F737-43. PubMed ID: 1590418 [TBL] [Abstract][Full Text] [Related]
4. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Hayashi T; Suzuki A; Shoji T; Togawa M; Okada N; Tsubakihara Y; Imai E; Hori M Am J Kidney Dis; 2000 Feb; 35(2):250-6. PubMed ID: 10676724 [TBL] [Abstract][Full Text] [Related]
5. 2004 Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients. Gejyo F; Saito A; Akizawa T; Akiba T; Sakai T; Suzuki M; Nishi S; Tsubakihara Y; Hirakata H; Bessho M; Ther Apher Dial; 2004 Dec; 8(6):443-59. PubMed ID: 15663544 [TBL] [Abstract][Full Text] [Related]
6. [Clinical and economic significance of iron replacement in anemia treated with recombinant human erythropoietin in patients on hemodialysis]. Vanková S; Safárová R; Horácková M; Herink J; Rychlík I; Bahbouh R; Půtová I Cas Lek Cesk; 2001 Apr; 140(7):209-13. PubMed ID: 11374225 [TBL] [Abstract][Full Text] [Related]
7. Recombinant human erythropoietin resistance in hemodialysis. Effects of paired filtration dialysis. Carozzi S; Nasini MG; Santoni O; Tirotta A; Sanna A ASAIO J; 1997; 43(5):M535-8. PubMed ID: 9360100 [TBL] [Abstract][Full Text] [Related]
8. Hemodynamic and volume changes by recombinant human erythropoietin (rHuEPO) in the treatment of anemic hemodialysis patients. Hori K; Onoyama K; Iseki K; Fujimi S; Fujishima M Clin Nephrol; 1990 Jun; 33(6):293-8. PubMed ID: 2376091 [TBL] [Abstract][Full Text] [Related]
9. Does parathyroid hormone affect erythropoietin therapy in dialysis patients? Al-Hilali N; Al-Humoud H; Ninan VT; Nampoory MR; Puliyclil MA; Johny KV Med Princ Pract; 2007; 16(1):63-7. PubMed ID: 17159367 [TBL] [Abstract][Full Text] [Related]
10. [Efficacy and safety of long-term erythropoietin therapy in chronic hemodialysis patients with renal anemia]. Ohkubo M; Ishimitsu T; Kawaguchi T; Abe M; Yagi S Nihon Jinzo Gakkai Shi; 1993 Feb; 35(2):171-7. PubMed ID: 8315880 [TBL] [Abstract][Full Text] [Related]
11. Factors contributing to higher hematocrit levels in hemodialysis patients not receiving recombinant human erythropoietin. Takeda A; Toda T; Shinohara S; Mogi Y; Matsui N Am J Kidney Dis; 2002 Jul; 40(1):104-9. PubMed ID: 12087567 [TBL] [Abstract][Full Text] [Related]
12. Secular trends in recombinant erythropoietin therapy among the U.S. hemodialysis population: 1990-1996. Cotter DJ; Thamer M; Kimmel PL; Sadler JH Kidney Int; 1998 Dec; 54(6):2129-39. PubMed ID: 9853279 [TBL] [Abstract][Full Text] [Related]
14. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. Ifudu O; Feldman J; Friedman EA N Engl J Med; 1996 Feb; 334(7):420-5. PubMed ID: 8552143 [TBL] [Abstract][Full Text] [Related]
15. Depressed cerebral oxygen metabolism in patients with chronic renal failure: a positron emission tomography study. Kanai H; Hirakata H; Nakane H; Fujii K; Hirakata E; Ibayashi S; Kuwabara Y Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S129-33. PubMed ID: 11576938 [TBL] [Abstract][Full Text] [Related]
16. Effects of recombinant human erythropoietin (rHuEPO) on nutritional status of hemodialysis patients: investigation of direct anabolic effects of rHuEPO. Usuba T; Kuno T; Higuchi T; Kikuchi F; Nagura Y; Kanmatsuse K; Takahashi S Nihon Jinzo Gakkai Shi; 1994 Nov; 36(11):1288-95. PubMed ID: 7853762 [TBL] [Abstract][Full Text] [Related]
17. Effects of changes in arterial O2 content on cerebral blood flow in the lamb. Jones MD; Traystman RJ; Simmons MA; Molteni RA Am J Physiol; 1981 Feb; 240(2):H209-15. PubMed ID: 7468816 [TBL] [Abstract][Full Text] [Related]
18. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Henry DH; Abels RI Semin Oncol; 1994 Apr; 21(2 Suppl 3):21-8. PubMed ID: 8202722 [TBL] [Abstract][Full Text] [Related]
20. Echocardiographic findings in hemodialysis patients treated with recombinant human erythropoietin: proposal for a hematocrit most beneficial to hemodynamics. Tagawa H; Nagano M; Saito H; Umezu M; Yamakado M Clin Nephrol; 1991 Jan; 35(1):35-8. PubMed ID: 2007294 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]